Pay in 4 interest-free payments of $7.27 Learn more
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20
Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline
At Noom, we believe behavior is essential to lasting change
Traditional use in cosmetic formulations does not establish efficacy for metabolic or appetite-related outcomes
Its emergence marks a move toward multi-pathway targeted weight management treatments
(Note: We do not accept Medicare or Medicaid)
Do not try to fix it by adding more BAC water that does not solve a pH problem
